Moderna Plans Vaccines Against 15 Pathogens With Future Pandemic Potential - Moderna (NASDAQ:MRNA)

Moderna Inc (NASDAQ: MRNA) plans to develop and begin testing vaccines targeting 15 pathogens identified as the biggest public health risk by WHO and CEPI by 2025.
The Company also said it would permanently wave its COVID-19 vaccine patents for shots intended for certain low- and middle-income countries.
At its global public health strategy, Moderna also said it would make its messenger RNA (mRNA) technology available to researchers working on new vaccines for emerging and neglected diseases through a program called mRNA Access.
Related: Moderna To Set Up mRNA Vaccine Manufacturing Facility In Kenya.
Moderna is already collaborating with partners on vaccines against some of the 15 pathogens, including Chikungunya, Crimean-Congo hemorrhagic fever, Dengue, Ebola, Malaria, Marburg, Lassa fever, MERS, and COVID-19.
Moderna said it would make that pledge permanent for the 92 low- and middle-income countries that qualify for assistance under the COVAX Advance Market Commitment (AMC) led by the GAVI vaccine alliance.
Price Action: MRNA shares are down 1.91% at $124.05 during the premarket session on the last check Tuesday.
Photo by mufidpwt via Pixaby

To add Benzinga News as your preferred source on Google, click here.